Systematic Pain Assessment in Nursing Home Residents With Advanced Dementia

Overview

It is estimated that 45-80 % of nursing home residents have substantial pain at any given time. Residents with impaired cognition have been found to report chronic pain more often, more frequent and more severe, compared to residents with normal cognition. Approximately 3/4 of permanent residents in nursing homes in Norway have developed dementia. The burden of dementia is often compounded by painful conditions. Despite over a decade of research on the subject, inadequate pain assessment and management remain significant problems among institutionalized older adults, with and without dementia. The poor pain management in patients with dementia has been attributed, at least in part, to difficulties with, and lack of, pain assessment in this population. Therefore, this study seek to determine the effect of regular pain assessment.

Full Title of Study: “Systematic Pain Assessment in Nursing Home Residents With Advanced Dementia; Effect on Pain Management and Patient Outcomes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: June 1, 2016

Detailed Description

The aim of the study is to determine the effect of regular pain assessment on pain management interventions applied and patient outcomes among patient with severe dementia.

A cluster randomized controlled trial will be conducted. A cluster is defined as a single independent nursing home. The clusters will be randomly assigned to either the experimental or control condition. Appropriate information will be given to both the intervention and the control group. All nurses in the experimental conditions will be taught how to administer the DOLOPLUS-2. The study will start after the initial education session. During the 3-month study period, the participating nursing staff will be asked to complete the DOLOPLUS-2 regularly. The control groups will receive standard methods of care. Data collection at baseline and at 4, 8 and 12 months.

Interventions

  • Other: Pain assessment
    • Pain assessment with assessment tools

Arms, Groups and Cohorts

  • Experimental: ITreatment arm: Pain Assessment
    • Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
  • No Intervention: Control arm: No treatment
    • Treatment us usual

Clinical Trial Outcome Measures

Primary Measures

  • Change in analgesic intake measured in Defined Daily Dose (DDD) or a similar measure from baseline to 12 weeks. Will be assessed in both the Intervention and Control group.
    • Time Frame: 12 weeks
  • Change in pain score on the Dolplus-2 pain scale, and change in proportion scoring ≥ 5 on the Doloplus-2 scale from baseline to 12 week. Will be assessed in both the Intervention and Control group.
    • Time Frame: 12 weeks

Secondary Measures

  • Change in psychotropic drug use from baseline to 12 weeks. Will be assessed in both the Intervention and Control group
    • Time Frame: 12 weeks
  • Change in NPS from baseline to 4, 8, 12 weeks. Will be assessed in both the Intervention and Control group
    • Time Frame: 4, 8, 12 weeks
  • Change in agitation measured with Brief Agitation Rating Scale (BARS) from baseline to 4 to 8 to 12 weeks. Will be assessed in both the Intervention and Control group.
    • Time Frame: 4, 8, 12 weeks
  • Change in QoL measured with QUALID from baseline to 12 weeks. Will be assessed in both the Intervention and Control group.
    • Time Frame: 12 weeks
  • Change in personal activity of daily living measured with the Physical Self Management Scale from baseline to 12 weeks. Will be assessed in both the Intervention and Control group.
    • Time Frame: 12 weeks
  • Nurses evaluation of systematic pain assessment tools by using a questionnaire developed for this study. Will be assessed in both the Intervention and Control group
    • Time Frame: 12 weeks
  • Pain management intervention applied when pain is detected with pain assessment tool Doloplus-2. Will be assessed for the Intervention group
    • Time Frame: 12 weeks
  • Validity and reliability of the Doloplus-2 pain scale.
    • Time Frame: 12 weeks
  • Convergent validity of three pain scales: the Doloplus-2, the Mobid-2 and the Checklist for non-verbal pain behavior.
    • Time Frame: Baseline – 12 weeks
  • Association between variables; pain, agitation, NPS, depression, ADL, QoL, analgesic use, psychotropic use Will be assessed in both the Intervention and Control group.
    • Time Frame: Baseline and 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 65 years old
  • Dementia diagnosis
  • Severe language impairment/non-communicative
  • Clinically significant pain and/or behavioral symptoms: a score of at least 44 on the Norwegian version of the Cohen-Mansfield Agitation Inventory (CMAI),
  • or a score of at least 4 (frequency × severity) on items of the Neuropsychiatric Inventory – Nursing Home Version (NPI-NH),
  • or an indication of clinically significant pain (≥ 5) according to the DOLOPLUS-2 at baseline

Exclusion Criteria

  • Short term stay, < 4 weeks
  • Primary psychiatric diagnosis
  • Delirium

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oslo Metropolitan University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Liv Halvorsrud, Associate Professor, PhD – Oslo Metropolitan University
  • Overall Official(s)
    • Liv Halvorsrud, PhD, Principal Investigator, Associate Professor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.